NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for ...
NC318 was well tolerated Single agent activity observed in multiple tumor types, including a CR and a PR in NSCLC Initiated Phase 2 portion of the Phase 1/2 monotherapy trial and plans for a combo trial with standard of care chemotherapies BELTSVILLE, Md., …